Query: stroke

Filtered By:
Source1: The American Journal of Emergency Medicine
Drug: Warfarin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 4 results found since Jan 2013.

Throwing it in reverse: An update on reversal of oral factor Xa inhibitors
In recent years, the use of oral Factor Xa (FXa) inhibitors such as rivaroxaban and apixaban, have seen more extensive utilization for stroke prevention in non-valvular atrial fibrillation and the prevention/treatment of venous thromboembolisms [1,2]. Some studies have shown a similar bleed risk between FXa inhibitors and warfarin while other studies demonstrated a decreased risk for a bleed with FXa inhibitors. Despite a possible decreased risk, the paucity of data available for treating an acute major bleed due to FXa inhibitors has led some clinicians to shy away from their use.
Source: The American Journal of Emergency Medicine - April 8, 2019 Category: Emergency Medicine Authors: Brian W. Gilbert, Jacob A. Reeder, Mohammed A. Alkhalifah, David A. Moran, Michael A. Corvino Source Type: research

Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis
This study describes a cohort of patients with FXa inhibitor-associated life-threatening bleeding events, their clinical characteristics, interventions and outcomes.
Source: The American Journal of Emergency Medicine - August 19, 2017 Category: Emergency Medicine Authors: Truman J. Milling, Carol L. Clark, Charles Feronti, Shlee S. Song, Sam S. Torbati, Gregory J. Fermann, Jeffrey Weiss, Dony Patel Source Type: research

Stroke prevention in real-life practice
We have greatly enjoyed reading the recently published article by McIntyre et al [1] . The authors distributed a 16-question, Web-based survey to Canadian residency programs and each scenario involved a 76-year-old man with new atrial fibrillation (AF) and a CHADS2 score of 3. The authors revealed the discordance between clinical guidelines for stroke prevention in AF and the practice of Canadian emergency medicine residents. Despite ranking the risk of adverse events as their most important consideration and the superior safety profile of those non –vitamin K antagonist oral anticoagulants (NOACs), residents underused ...
Source: The American Journal of Emergency Medicine - June 6, 2016 Category: Emergency Medicine Authors: Özcan Başaran, Volkan Doğan, Eda Özlek, Bülent Özlek, Murat Biteker Tags: Correspondence Source Type: research

Stroke Prevention in Real-life Practice
We have greatly enjoyed reading the recently published article by McIntyre et al. (1). The authors distributed a 16-question, web-based survey to Canadian residency programs and each scenario involved a 76-year-old man with new atrial fibrillation (AF) and a CHADS2 score of 3. The authors revealed the discordance between clinical guidelines for stroke prevention in AF and the practice of Canadian emergency medicine residents. Despite ranking the risk of adverse events as their most important consideration and the superior safety profile of that non-vitamin K antagonist oral anticoagulants (NOACs), residents underused this ...
Source: The American Journal of Emergency Medicine - June 6, 2016 Category: Emergency Medicine Authors: Özcan Başaran, Volkan Doğan, Eda Özlek, Bülent Özlek, Murat Biteker Source Type: research